Neurobiological To Revive Viprinex Stroke Trials Following Empire Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
New Phase III trials for Abbott's former anticoagulant will be based on meta-analyses of previous Phase II and III trials of the pit viper venom-derived agent, Neurobiological Technologies says. Empire licensed Viprinex from Abbott in 2002.
You may also be interested in...
Neurobiological Tech Consolidates Phase III Trials To Hasten Viprinex Findings
Combining two trials will produce interim data analysis expected next January.
Neurobiological Tech Consolidates Phase III Trials To Hasten Viprinex Findings
Combining two trials will produce interim data analysis expected next January.
Neurobiological Consolidates Phase III Trials To Hasten Viprinex Findings
By combining data from two structurally similar Phase III trials, Neurobiological Technologies will hasten the pace at which it can make a definitive call on Viprinex (ancrod) and possibly secure a development partner for the ischemic stroke drug